499 related articles for article (PubMed ID: 26036643)
1. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.
Tricker EM; Xu C; Uddin S; Capelletti M; Ercan D; Ogino A; Pratilas CA; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2015 Sep; 5(9):960-971. PubMed ID: 26036643
[TBL] [Abstract][Full Text] [Related]
2. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
3. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
4. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
7. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.
Yamada T; Takeuchi S; Fujita N; Nakamura A; Wang W; Li Q; Oda M; Mitsudomi T; Yatabe Y; Sekido Y; Yoshida J; Higashiyama M; Noguchi M; Uehara H; Nishioka Y; Sone S; Yano S
Oncogene; 2013 Sep; 32(37):4427-35. PubMed ID: 23045273
[TBL] [Abstract][Full Text] [Related]
8. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D; Choi HG; Yun CH; Capelletti M; Xie T; Eck MJ; Gray NS; Jänne PA
Clin Cancer Res; 2015 Sep; 21(17):3913-23. PubMed ID: 25948633
[TBL] [Abstract][Full Text] [Related]
9. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
[TBL] [Abstract][Full Text] [Related]
10. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
11. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Sos ML; Rode HB; Heynck S; Peifer M; Fischer F; Klüter S; Pawar VG; Reuter C; Heuckmann JM; Weiss J; Ruddigkeit L; Rabiller M; Koker M; Simard JR; Getlik M; Yuza Y; Chen TH; Greulich H; Thomas RK; Rauh D
Cancer Res; 2010 Feb; 70(3):868-74. PubMed ID: 20103621
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan D; Xu C; Yanagita M; Monast CS; Pratilas CA; Montero J; Butaney M; Shimamura T; Sholl L; Ivanova EV; Tadi M; Rogers A; Repellin C; Capelletti M; Maertens O; Goetz EM; Letai A; Garraway LA; Lazzara MJ; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2012 Oct; 2(10):934-47. PubMed ID: 22961667
[TBL] [Abstract][Full Text] [Related]
13. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
14. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
[TBL] [Abstract][Full Text] [Related]
18. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
Cortot AB; Repellin CE; Shimamura T; Capelletti M; Zejnullahu K; Ercan D; Christensen JG; Wong KK; Gray NS; Jänne PA
Cancer Res; 2013 Jan; 73(2):834-43. PubMed ID: 23172312
[TBL] [Abstract][Full Text] [Related]
19. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
Regales L; Balak MN; Gong Y; Politi K; Sawai A; Le C; Koutcher JA; Solit DB; Rosen N; Zakowski MF; Pao W
PLoS One; 2007 Aug; 2(8):e810. PubMed ID: 17726540
[TBL] [Abstract][Full Text] [Related]
20. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
